Tananbaum James B.'s Form 4 filing
Pardes Biosciences, Inc. (PRDS) · filed Apr 6, 2023
- Accession no.
- 0001213900-23-028117
- Filed
- Apr 6, 2023, 9:08 PM ET
- Trade date
- Apr 5, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $1.16M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tananbaum James B.CIK 0001581754 | Director, 10% Owner |
| Foresite Capital Opportunity Fund V, L.P.CIK 0001792205 | 10% Owner |
| Foresite Capital Opportunity Management V, LLCCIK 0001792207 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 5, 2023 | Common Stock | PPurchaseAcquired | +773,952 | $1.50 | +$1,160,928 | 8,773,134 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.